的核苷的替诺福韦和恩替卡韦治疗第一年的结果（t）的IDE -

StephenW

Year : 2015  |  Volume : 21  |  Issue : 6  |  Page : 396-399

Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis

Zeynal Dogan, Levent Filik, Bilal Ergül, Murat Sarikaya
Department of Gastroenterology, Ankara Education and Research Hospital, Altındağ, Ankara, Turkey

Correspondence Address:
Zeynal Dogan
Department of Gastroenterology, Ankara Education and Research Hospital, Ulucanlar Street, District Sukriye, Altindag, Ankara - 06230
Turkey


Background/Aim: Hepatic steatosis may influence the response to antivirals in chronic hepatitis B patients. This study aimed to compare the efficacy of entecavir and tenofovir in nucleos(t) ide-naive chronic hepatitis B patients with hepatosteatosis during 48 weeks of therapy. Patients and Methods: We retrospectively reviewed our data for chronic hepatitis B patients. Nucleos(t) ide-naive patients with hepatosteatosis who took entecavir or tenofovir for at least 48 weeks were included. We compared entecavir and tenofovir after 48 weeks of therapy with respect to virological, biochemical, and serological responses in patients with hepatosteatosis. Results: Of the 63 patients, 21 received entecavir and 42 received tenofovir. Baseline characteristics of the patients were similar except for body mass index. At the end of week 48, there was no statistically significant difference between tenofovir and entecavir treatment regarding total HBV-DNA negativity and alanine transferase normalization in patients with chronic hepatitis B and hepatosteatosis. Conclusions: Entecavir and tenofovir are similarly effective in nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis after 48 weeks of therapy.

StephenW

年份：2015年|体积：21 |问题：6 |页：396-399

的核苷的替诺福韦和恩替卡韦治疗第一年的结果（t）的IDE - 天真慢性乙型肝炎患者hepatosteatosis比较

Zeynal多甘，勒Filik，比拉尔Ergül，穆拉特Sarikaya
消化内科，安卡拉的教育和研究医院，Altındağ，安卡拉，土耳其系

通讯地址：
Zeynal多安
消化内科，安卡拉的教育和研究医院，Ulucanlar街，区Sukriye，Altindag，安卡拉部 - 06230
火鸡


背景/目的：脂肪肝可能影响应对慢性乙型肝炎患者的抗病毒药物。本研究的目的在48周治疗恩替卡韦和替诺福韦的核苷（酸）IDE-天真慢性乙型肝炎患者hepatosteatosis的疗效比较。患者和方法：我们回顾了慢性乙肝患者我们的数据。核苷（酸）IDE初治患者与hepatosteatosis谁了恩替卡韦或替诺福韦至少48周时包括在内。我们比较恩替卡韦和替诺福韦48周治疗相对于病毒学，生化和血清学反应后患者hepatosteatosis。结果：在63例患者中，21接受恩替卡韦和42获得替诺福韦。患者基线特征，除了身体质量指数相似。在48周的末尾，有关于总HBV-DNA阴性和丙氨酸转氨酶正常化慢性乙肝和hepatosteatosis替诺福韦和恩替卡韦治疗间无统计学差异显著。结论：恩替卡韦和替诺福韦也同样有效的核苷（酸）IDE-天真慢性乙型肝炎患者hepatosteatosis 48周治疗后。